Management of Resectable Gastrointestinal Stromal Tumor

Hematology/Oncology Clinics of North America

Volumn 23, Issue 1, 2009, Pages 79-96

  Chaudhry, Umer I ^a   DeMatteo, Ronald P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Gastrointestinal stromal tumor; KIT; Mutation; PDGFR; Surgery

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR;

CANCER RADIOTHERAPY; DISEASE FREE SURVIVAL; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REVIEW; SCHWANN CELL; SMOOTH MUSCLE FIBER;

COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PIPERAZINES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 60549114335     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2009.01.001     Document Type: Review

References (79)

1. Mazur M.T., and Clark H.B. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 7 6 (1983) 507-519
2. Howe J.R., Karnell L.H., and Scott-Conner C. Small bowel sarcoma: analysis of survival from the National Cancer Data Base. Ann Surg Oncol 8 6 (2001) 496-508
3. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279 5350 (1998) 577-580
4. Suster S. Gastrointestinal stromal tumors. Semin Diagn Pathol 13 4 (1996) 297-313
5. Rubin B.P., Singer S., Tsao C., et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61 22 (2001) 8118-8121
6. Antonescu C.R., Sommer G., Sarran L., et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 9 9 (2003) 3329-3337
7. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299 5607 (2003) 708-710
8. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344 14 (2001) 1052-1056
9. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 7 (2002) 472-480
10. DeMatteo R.P., Lewis J.J., Leung D., et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231 1 (2000) 51-58
11. Thomas R.M., and Sobin L.H. Gastrointestinal cancer. Cancer 75 1 Suppl (1995) 154-170
12. Demetri G.D., Baker L.H., Benjamin R.S., et al. Soft tissue sarcoma. J Natl Compr Canc Netw 5 4 (2007) 364-399
13. Demetri G.D., Benjamin R.S., Blanke C.D., et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5 Suppl 2 (2007) S1-S29 [quiz S30]
14. Nilsson B., Bumming P., Meis-Kindblom J.M., et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 103 4 (2005) 821-829
15. Nishida T., Hirota S., Taniguchi M., et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 19 4 (1998) 323-324
16. Chompret A., Kannengiesser C., Barrois M., et al. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology 126 1 (2004) 318-321
17. Takazawa Y., Sakurai S., Sakuma Y., et al. Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen's disease). Am J Surg Pathol 29 6 (2005) 755-763
18. Carney J.A. The triad of gastric epithelioid leiomyosarcoma, functioning extra-adrenal paraganglioma, and pulmonary chondroma. Cancer 43 1 (1979) 374-382
19. Emory T.S., Sobin L.H., Lukes L., et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 23 1 (1999) 82-87
20. Graadt van Roggen J.F., van Velthuysen M.L., and Hogendoorn P.C. The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol 54 2 (2001) 96-102
21. Miettinen M., Sarlomo-Rikala M., Sobin L.H., et al. Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. Am J Surg Pathol 24 2 (2000) 211-222
22. Agaram N.P., Laquaglia M.P., Ustun B., et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res 14 10 (2008) 3204-3215
23. Ueyama T., Guo K.J., Hashimoto H., et al. A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors. Cancer 69 4 (1992) 947-955
24. Hurlimann J., and Gardiol D. Gastrointestinal stromal tumours: an immunohistochemical study of 165 cases. Histopathology 19 4 (1991) 311-320
25. Yagihashi S., Kimura M., Kurotaki H., et al. Gastric submucosal tumours of neurogenic origin with neuroaxonal and Schwann cell elements. J Pathol 153 1 (1987) 41-50
26. Kindblom L.G., Remotti H.E., Aldenborg F., et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152 5 (1998) 1259-1269
27. Bickenbach K., Wilcox R., Veerapong J., et al. A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy. J Gastrointest Surg 11 6 (2007) 758-766
28. Antonescu C.R., Busam K.J., Francone T.D., et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 121 2 (2007) 257-264
29. Fletcher C.D., Berman J.J., Corless C., et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33 5 (2002) 459-465
30. Katz S.C., and DeMatteo R.P. Gastrointestinal stromal tumors and leiomyosarcomas. J Surg Oncol 97 4 (2008) 350-359
31. van der Zwan S.M., and DeMatteo R.P. Gastrointestinal stromal tumor: 5 years later. Cancer 104 9 (2005) 1781-1788
32. Medeiros F., Corless C.L., Duensing A., et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 28 7 (2004) 889-894
33. Tzen C.Y., and Mau B.L. Analysis of CD117-negative gastrointestinal stromal tumors. World J Gastroenterol 11 7 (2005) 1052-1055
34. Dematteo R.P., Gold J.S., Saran L., et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 112 3 (2008) 608-615
35. Franquemont D.W. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 103 1 (1995) 41-47
36. Ranchod M., and Kempson R.L. Smooth muscle tumors of the gastrointestinal tract and retroperitoneum: a pathologic analysis of 100 cases. Cancer 39 1 (1977) 255-262
37. Sommer G., Agosti V., Ehlers I., et al. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the KIT receptor tyrosine kinase. Proc Natl Acad Sci U S A 100 11 (2003) 6706-6711
38. Tsujimura T., Morimoto M., Hashimoto K., et al. Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. Blood 87 1 (1996) 273-283
39. Tian Q., Frierson Jr. H.F., Krystal G.W., et al. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 154 6 (1999) 1643-1647
40. Kanakura Y., Ikeda H., Kitayama H., et al. Expression, function, and activation of the proto-oncogene c-kit product in human leukemia cells. Leuk Lymphoma 10 1-2 (1993) 35-41
41. Cohen P.S., Chan J.P., Lipkunskaya M., et al. Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group. Blood 84 10 (1994) 3465-3472
42. Lux M.L., Rubin B.P., Biase T.L., et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 156 3 (2000) 791-795
43. Joensuu H. Gastrointestinal stromal tumor (GIST). Ann Oncol 17 Suppl 10 (2006) x280-x286
44. Breiner J.A., Meis-Kindblom J., Kindblom L.G., et al. Loss of 14q and 22q in gastrointestinal stromal tumors (pacemaker cell tumors). Cancer Genet Cytogenet 120 2 (2000) 111-116
45. Gold J.S., and Dematteo R.P. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg 244 2 (2006) 176-184
46. Dematteo R.P., Maki R.G., Antonescu C., et al. Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor. Curr Probl Surg 40 3 (2003) 144-193
47. Miettinen M., El-Rifai W., HL Sobin L., et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 33 5 (2002) 478-483
48. Shiu M.H., Farr G.H., Papachristou D.N., et al. Myosarcomas of the stomach: natural history, prognostic factors, and management. Cancer 49 1 (1982) 177-187
49. Ng E.H., Pollock R.E., Munsell M.F., et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 215 1 (1992) 68-77
50. Rudolph P., Gloeckner K., Parwaresch R., et al. Immunophenotype, proliferation, DNA ploidy, and biological behavior of gastrointestinal stromal tumors: a multivariate clinicopathologic study. Hum Pathol 29 8 (1998) 791-800
51. Goldblum J.R., and Appelman H.D. Stromal tumors of the duodenum. A histologic and immunohistochemical study of 20 cases. Am J Surg Pathol 19 1 (1995) 71-80
52. Kiyabu M.T., Bishop P.C., Parker J.W., et al. Smooth muscle tumors of the gastrointestinal tract. Flow cytometric quantitation of DNA and nuclear antigen content and correlation with histologic grade. Am J Surg Pathol 12 12 (1988) 954-960
53. Cooper P.N., Quirke P., Hardy G.J., et al. A flow cytometric, clinical, and histological study of stromal neoplasms of the gastrointestinal tract. Am J Surg Pathol 16 2 (1992) 163-170
54. Gunther T., Schneider-Stock R., Hackel C., et al. Telomerase activity and expression of hTRT and hTR in gastrointestinal stromal tumors in comparison with extragastrointestinal sarcomas. Clin Cancer Res 6 5 (2000) 1811-1818
55. Prenen H., Deroose C., Vermaelen P., et al. Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography. Anticancer Res 26 2A (2006) 1247-1252
56. Tran T., Davila J.A., and El-Serag H.B. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1458 cases from 1992 to 2000. Am J Gastroenterol 100 1 (2005) 162-168
57. Ng E.H., Pollock R.E., and Romsdahl M.M. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer 69 6 (1992) 1334-1341
58. DeMatteo R., Ronald P., Maki R.G., et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 245 (2007) 347-352
59. DeMatteo R.P. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol 9 9 (2002) 831-839
60. Edmonson J.H. Chemotherapeutic approaches to soft tissue sarcomas. Semin Surg Oncol 10 5 (1994) 357-363
61. Edmonson J.H., Ryan L.M., Blum R.H., et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11 7 (1993) 1269-1275
62. Demetri G.D. ET-743: the US experience in sarcomas of soft tissues. Anticancer Drugs 13 Suppl 1 (2002) S7-S9
63. DeMatteo R.P., Shah A., Fong Y., et al. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 234 4 (2001) 540-547 [discussion: 547-8]
64. D'Amato G., Steinert D.M., McAuliffe J.C., et al. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 12 1 (2005) 44-56
65. Savage D.G., and Antman K.H. Imatinib mesylate-a new oral targeted therapy. N Engl J Med 346 9 (2002) 683-693
66. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 14 (2001) 1031-1037
67. DeMatteo RP, Owzar, K, Antonescu, CR, et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000. 2008 Paper presented at the Gastrointestinal Cancers Symposium, January 25-27, 2008, Orlando, FL.
68. Dematteo R. Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000. Presented at ASCO, May 13-17, 2005, Orlando, FL.
69. DeMatteo RP, Owzar K, Maki R, et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. Presented at the 2007 ASCO Annual Meeting, June 1-5, 2007, Chicago, IL.
70. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364 9440 (2004) 1127-1134
71. van Oosterom A.T., Judson I., Verweij J., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358 9291 (2001) 1421-1423
72. Gronchi A., Fiore M., Miselli F., et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 245 3 (2007) 341-346
73. Raut C.P., Posner M., Desai J., et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24 15 (2006) 2325-2331
74. La Cense A., Perol D., and Ray-Coquard I. Interruption of imatinib (IM) in GIST patients with advanced disease: updated results of the prospective French Sarcoma Group randomized phase III trial on survival and quality of life. J Clin Oncol 23 16S (2005) 9031
75. Van Glabbeke M., Verweij J., Casali P.G., et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 23 24 (2005) 5795-5804
76. Judson I., and Demetri G. Advances in the treatment of gastrointestinal stromal tumours. Ann Oncol 18 Suppl 10 (2007) x20-x24
77. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 23 (2003) 4342-4349
78. Antonescu C.R., Besmer P., Guo T., et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11 11 (2005) 4182-4190
79. Prenen H., Cools J., Mentens N., et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 12 8 (2006) 2622-2627